Bicara Therapeutics (BCAX) Income from Continuing Operations (2023 - 2026)
Bicara Therapeutics' (BCAX) quarterly Income from Continuing Operations came in at 56211000.0 in Q1 2026, down 52.56% year-on-year from 118480093.02 in Q1 2025, and down 50.35% quarter-over-quarter from 37386000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 56211000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 52.56% year-over-year to 56211000.0 in Q1 2026; TTM through Mar 2026 was 157315000.0, a 70.38% decrease from a year earlier, with the FY2025 full-year figure at 137950000.0, down 102.88% from the prior year.
- Income from Continuing Operations slipped to 56211000.0 in Q1 2026 per BCAX's latest filing, from 37386000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 12440000.0 in Q4 2023 and bottomed at 56211000.0 in Q1 2026.
- The 4-year median for Income from Continuing Operations is 22845000.0 (2023), against an average of 27040090.91.
- Across the five-year window, Income from Continuing Operations gained 23.48% in 2024 and sank 194.58% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 12440000.0 in 2023, then plunged by 68.46% to 20957000.0 in 2024, then tumbled by 78.39% to 37386000.0 in 2025, then sank by 50.35% to 56211000.0 in 2026.
- Per Business Quant, the three latest BCAX Income from Continuing Operations figures stand at 56211000.0 (Q1 2026), 37386000.0 (Q4 2025), and 36330000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Bicara Therapeutics | 1.64 Bn | 1.64 Bn | - | -56.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.21 Mn |
| Dec 31, 2025 | -37.39 Mn |
| Sep 30, 2025 | -36.33 Mn |
| Jun 30, 2025 | -27.39 Mn |
| Mar 31, 2025 | -36.85 Mn |
| Dec 31, 2024 | -20.96 Mn |
| Sep 30, 2024 | -17.48 Mn |
| Jun 30, 2024 | -17.05 Mn |
| Mar 31, 2024 | -12.51 Mn |
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | -22.85 Mn |